Prospective study to compare antibiosis versus the association of N-acetylcysteine, D-mannose and Morinda citrifolia fruit extract in preventing urinary tract infections in patients submitted to urodynamic investigation

Archivio Italiano di Urologia e Andrologia

Volumn 89, Issue 1, 2017, Pages 45-50

  Palleschi, Giovanni ^a,b   Carbone, Antonio ^a,b   Zanello, Pier Paolo ^e   Mele, Rita ^a   Leto, Antonino ^a,b   Fuschi, Andrea ^a,b   Al Salhi, Yazan ^a,b   Velotti, Gennaro ^a,b   Al Rawashdah, Samer ^c   Coppola, Gianluca ^a,b   Maurizi, Angela ^a,b   Maruccia, Serena ^d   Pastore, Antonio L ^a,b  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b Uroresearch Association   (Italy)

^c MUTAH UNIVERSITY   (Jordan)

^d IRCCS POLICLINICO SAN DONATO   (Italy)

^e IRCCS Policlinico San Donato Milanese ^*

Author keywords

Biofilm; D mannose N acetylcysteine (NAC); Urinary Tract Infection (UTI); Urodynamic

Indexed keywords

ACETYLCYSTEINE; ANTIINFLAMMATORY AGENT; IMMUNOSTIMULATING AGENT; MANNOSE; MORINDA CITRIFOLIA EXTRACT; NUTRACEUTICAL; PRULIFLOXACIN; 1,3 DIOXOLANE DERIVATIVE; ANTIINFECTIVE AGENT; PIPERAZINE DERIVATIVE; PLANT EXTRACT; QUINOLONE DERIVATIVE;

ADOLESCENT; ADULT; AGED; ANTIBIOSIS; ANTIBIOTIC THERAPY; ARTICLE; CHILD; COMPARATIVE STUDY; CONTROLLED STUDY; FEMALE; HUMAN; INCIDENCE; INFANT; INFECTION PREVENTION; MAJOR CLINICAL STUDY; MALE; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; URINARY TRACT INFECTION; URINE CULTURE; URODYNAMICS; UROLOGIC EXAMINATION; ANTIBIOTIC PROPHYLAXIS; BACTERIUM ADHERENCE; CHEMISTRY; DRUG EFFECT; FRUIT; MIDDLE AGED; MORINDA; PHYSIOLOGY; PROCEDURES;

ACETYLCYSTEINE; AGED; ANTI-BACTERIAL AGENTS; ANTIBIOSIS; ANTIBIOTIC PROPHYLAXIS; BACTERIAL ADHESION; DIOXOLANES; FEMALE; FLUOROQUINOLONES; FRUIT; HUMANS; INCIDENCE; MALE; MANNOSE; MIDDLE AGED; MORINDA; PIPERAZINES; PLANT EXTRACTS; PROSPECTIVE STUDIES; URINARY TRACT INFECTIONS; URODYNAMICS;

EID: 85019219765     PISSN: 11243562     EISSN: 22824197     Source Type: Journal    
DOI: 10.4081/aiua.2017.1.45     Document Type: Article

References (21)

1. Lüthje P, Brauner A. Novel strategies in the prevention and treatment of urinary tract infections. Pathogens 2016; 5:E13.
2. Xia J, Gao J, Tang W. Nosocomial infection and its molecular mechanisms of antibiotic resistance. Biosci Trends. 2016; 10:14-21.
3. André M, Ahlqvist-Rastad J, Beermann B. Nedre urinvägsinfektion (UVI) hos kvinnor - Lower urinary tract infection (UTI) in women - Treatment recommendation. The Med. Prod Agency, Sweden 2007; 18.
4. Cheng MF, Chen WL, Huang IF, et al. Urinary tract infection in infants caused by extended-spectrum beta-lactamase-producing Escherichia coli: comparison between urban and rural hospitals. Pediatric Nephrol. 2016; 31:1305-12.
5. Iacovelli V, Gaziev G, Topazio L, et al. Nosocomial urinary tract infections: A review. Urol. 2014; 81:222-7.
6. Duszynska W, Rosenthal VD, Szczesny A, et al. Urinary tract infections in intensive care unit patients - a single centre. 3 year observational study according to the INICC project. Anaesth Intens Ther. 2016; 48:1-6.
7. Vigil HR, Hickling DR. Urinary tract infection in the neurogenic bladder. Transl Androl Urol. 2016; 5:72-87.
8. Harwalkar A, Gupta S, Rao A, et al. Prevalence of virulence factors and phylogenetic characterization of uropathogenic Escherichia coli causing urinary tract infection in patients with and without diabetes mellitus. Soc Trop Med Hyg. 2015; 109:769-74.
9. Graziottin A, Zanello PP, D'Errico G. Recurrent cystitis and vaginitis: role of biofilm and persister cells. From pathophysiology to new therapeutic strategies. Min Ginecol. 2014; 66:497-512.
10. Graziottin A, Zanello PP. Pathogenic biofilms as a triggers of recurrent vaginitis and cystitis. Proceedings oft he 20th World Congress on Controversies in Obstetrics, Gynecology & Infertility (COGI) 4-7 December 2014 Paris, France Monduzzi Editore, 2015.
11. Johnson TJ, Logue CM, Johnson JR, et al. Associations between multidrug resistance, plasmid content, and virulence potential among extraintestinal pathogenic and commensal Escherichia coli from humans and poultry. Foodborne Pathog Dis. 2012; 9:37-46.
12. Raditic DM. Complementary and integrative therapies for lower urinary tract diseases. Vet Clin North Am Small Anim Pract. 2015; 45:857-78.
13. Panneerselvam K, Etchison JR, Freeze HH. Human Fibroblasts Prefer Mannose over Glucose as a Source of Mannose for N-Glycosylation. J Biol Chem. 1997; 272: 23123-23129.
14. Alton G, Hasilik M, Niehues R, et al. Direct utilization of mannose for mammalian glycoprotein biosynthesis. Glycobiol 1998; 8:285-295.
15. Kranjcec B, Papeš D, Altarac S. D-mannose powder for prophylaxis of recurrent urinary tract infections in women: a randomized clin-ical trial. World J Urol. 2013; 32:79-84.
16. Altarac S, Papeš D. Use of D-mannose in prophylaxis of recurrent urinary tract infections (UTIs) in women. BJU Int. 2014; 113:9-10.
17. Porru D, Parmigiani A, Tinelli C, et al. Oral D-mannose in recurrent urinary tract infections in women: A pilot study. J Clin Urol. 2014; 20:1-6.
18. Palaniswamy U1, Lakkam SR1, Arya S1, Aravelli S1. Effectiveness of N-acetylcysteine, 2% chlorhexidine, and their combination as intracanal medicaments on Enterococcus faecalis biofilm. J Conserv Dent. 2016; 19:17-20.
19. Dinicola S, De Grazia S, Carlomagno G, Pintucci JP. N-acetylcysteine as powerful molecule to destroy bacterial biofilms. A systematic review. Eur Rev Med Pharmacol Sci. 2014; 18:2942-8.
20. Naves P, del Prado G, Huelves L, et al. Effects of human serum albumin, ibuprofen and N-acetyl-L-cysteine against biofilm formation by pathogenic Escherichia coli strains. J Hosp Infect. 2010; 76:165-70.
21. Abou Assi R, Darwis Y, Abdulbaqi IM, et al. Morinda citrifolia (Noni): A comprehensive review on its industrial uses, pharmacological activities, and clinical trials- Arab J Chem. 2015, in press.